Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.74 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.62 |
| ▸ | HTR1D | P28221 | 2/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR1E | P28566 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR5A | P47898 | 1/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deboxamet SCHEMBL29387753 | 1.00 | AKR1C2 (0.74) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL8270880 | 0.90 | AKR1C2 (0.74) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL8110763 | 0.87 | AKR1C2 (0.70) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL8401335 | 0.87 | AKR1C2 (0.70) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL30604527 | 0.86 | AKR1C2 (0.78) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL6825151 | 0.86 | AKR1C2 (0.78) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL7960856 | 0.85 | AKR1C2 (0.67) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| Deschlorobenzoyl Indomethacin SCHEMBL454792 | 0.85 | AKR1C2 (1.00) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL10205891 | 0.85 | AKR1C2 (0.80) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL4825986 | 0.85 | AKR1C2 (0.57) | AKR1C2MTNR1AMTNR1BHDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 734 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | claimed |
| US-8759326-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | claimed |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | claimed |
| US-8592400-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-26 | — | — | US | claimed |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | claimed |
| US-20120028932-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | claimed |
| EP-2400961-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097332-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | claimed |
| CN-1747731-A | Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders | ALTANA PHARMA AG (DE) | 2006-03-15 | — | — | CN | claimed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-4285962-A | ADMINISTERING 2-METHYL-5-METHOXY-INDOL-3-YLACETOHYDROXAMIC ACID | ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.P.A. (IT) | 1981-08-25 | — | — | US | claimed |
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250276957-A1 | CRYSTALLINE FORMS OF AN IL-17 INHIBITOR | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, CO., LTD. (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| EP-4577550-A1 | NOVEL NLRP3 INFLAMMASOME INHIBITORS | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20250206742-A1 | NLRP3 INFLAMMASOME INHIBITORS | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4565326-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RES INST (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119732956-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| EP-4526299-A1 | CRYSTALLINE FORMS OF AN IL-17 INHIBITOR | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| CN-119677725-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-113784957-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4499646-A1 | NLRP3 INFLAMMASOME INHIBITORS | Hangzhou Highlightll Pharmaceutical Co., Ltd (CN) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034114-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-12-17 | — | — | US | disclosed |
| CN-119137115-A | Crystalline forms of an IL-17 inhibitor | 诺华股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12157737-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2024-12-03 | — | — | US | disclosed |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| CN-114716544-B | Complement component C5 antibodies | 阿勒根公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240301370-A1 | Ligand Binding Molecules and Uses Thereof | VEGENICS PTY LIMITED (AU) | 2024-09-12 | — | — | US | disclosed |
| US-20240294652-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240279317-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-3827008-B1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024041460-A1 | NOVEL NLRP3 INFLAMMASOME INHIBITORS | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2024-02-29 | — | — | WO | disclosed |
| US-20240067627-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| WO-2024028782-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-02-08 | — | — | WO | disclosed |
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2024-02-08 | — | — | US | disclosed |
| US-11866739-B2 | Ligand binding molecules and uses thereof | VEGENICS PTY LIMITED (AU) | 2024-01-09 | — | — | US | disclosed |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2023-12-07 | — | — | US | disclosed |
| WO-2023209519-A1 | CRYSTALLINE FORMS OF AN IL-17 INHIBITOR | NOVARTIS AG (CH) | 2023-11-02 | — | — | WO | disclosed |
| EP-4237417-A1 | INTERLEUKIN-17 INHIBITORS | Novartis AG (CH) | 2023-09-06 | — | — | EP | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230124150-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220374391-A1 | INFORMATION MANAGEMENT SYSTEM | THE MILLENNIUM GROUP OF DELAWARE, INC. | 2022-11-24 | — | — | US | disclosed |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| EP-4008726-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022091056-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2022-05-05 | — | — | WO | disclosed |
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RESEARCH INSTITUTE | 2022-03-24 | — | — | US | disclosed |
| EP-3969441-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-11274078-B2 | Drug for treating tumor diseases and having antibacterial antivirus anti-inflammatory effects | SHI JIANYOU (CN) | 2022-03-15 | — | — | US | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| EP-3165539-B1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K A INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11180564-B2 | IL-17 Receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210101965-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | XENCOR, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-20200362045-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200317762-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10752678-B2 | Complement component C5 antibodies | ALLERGAN, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3693381-A1 | LIGAND BINDING MOLECULES AND USES THEREOF | Vegenics Pty Limited (AU) | 2020-08-12 | — | — | EP | disclosed |
| EP-3107935-B1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200165584-A1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2020-05-28 | — | — | US | disclosed |
| EP-3653643-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10604563-B2 | Nucleic acids encoding anti-complement Factor Bb antibodies | ALLERGAN, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2020-02-13 | — | — | US | disclosed |
| CN-110464724-A | The method for treating autoimmunity, breathing and/or inflammatory conditions by sucking N-oxide of roflumilast | INCOZEN THERAPEUTICS PVT LTD | 2019-11-19 | — | — | CN | disclosed |
| CN-110403922-A | The method for treating autoimmunity, breathing and/or inflammatory conditions by sucking N-oxide of roflumilast | INCOZEN THERAPEUTICS PVT LTD | 2019-11-05 | — | — | CN | disclosed |
| CN-106255689-B | Heteroaryl SYK Inhibitors | 勃林格殷格翰国际有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110183440-A | Heteroaryl SYK inhibitor | 勃林格殷格翰国际有限公司 | 2019-08-30 | — | — | CN | disclosed |
| US-20190262426-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA A/S (DK) | 2019-08-29 | — | — | US | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-20190151404-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEEASE | SCHEPENS EYE RESEARCH INSTITUTE | 2019-05-23 | — | — | US | disclosed |
| EP-3119766-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3054982-B1 | HYDROGEL-LINKED IL-1RA PRODRUG | ASCENDIS PHARMA AS (DK) | 2019-05-01 | — | — | EP | disclosed |
| US-20190071492-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-10208122-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10179160-B2 | Therapeutic compositions for the treatment of dry eye disease | SCHEPENS EYE RESEARCH INSTITUTE (US) | 2019-01-15 | — | — | US | disclosed |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| US-10093724-B2 | Methods of treating a complement associated eye condition by administering complement factor Bb antibodies | ALLERGAN, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180222969-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | XENCOR, INC. | 2018-08-09 | — | — | US | disclosed |
| EP-3347353-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| CN-108026080-A | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments | 勃林格殷格翰国际有限公司 | 2018-05-11 | — | — | CN | disclosed |
| US-9932395-B2 | Nucleic acids encoding complement component C5 antibodies | ALLERGAN, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20180072754-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9914735-B2 | Heteroaryl Syk inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-20180057576-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S (DK) | 2018-02-15 | — | — | US | disclosed |
| EP-3277665-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2018-02-07 | — | — | EP | disclosed |
| CN-107635961-A | Indoles analog and its application method as 5 oxo ETE receptor antagonists | 皇家学习促进学会/麦吉尔大学 | 2018-01-26 | — | — | CN | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20170349886-A1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LIMITED (AU) | 2017-12-07 | — | — | US | disclosed |
| US-9802954-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20170306007-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9796776-B2 | Complement factor Bb antibodies | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| CN-107207585-A | complement component C5 antibody | 阿勒根公司 | 2017-09-26 | — | — | CN | disclosed |
| US-9745558-B2 | VEGFR-3 ligand binding molecules and uses thereof | VEGENICS PTY LIMITED (AU) | 2017-08-29 | — | — | US | disclosed |
| CN-104151428-B | IL 17RA IL 17RB antagonists and application thereof | 麒麟-安姆根有限公司 | 2017-07-14 | — | — | CN | disclosed |
| US-9701743-B2 | Complement component C5 antibodies | ALLERGAN, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3165539-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | Kirin-Amgen, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20170114140-A1 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | KIRIN-AMGEN INC (US) | 2017-04-27 | — | — | US | disclosed |
| EP-2538965-B1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RES INST (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2017042100-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | WO | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-2487188-B1 | IL-17 receptor A antigen binding proteins | KIRIN-AMGEN INC (US) | 2017-03-08 | — | — | EP | disclosed |
| CN-106414487-A | Ligand binding molecules and uses thereof | 韦格尼奇有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-3119766-A1 | HETEROARYL SYK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119772-A1 | HETEROARYL SIK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119765-A1 | HETEROARYL SYK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2002846-B1 | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases | AMGEN INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20170008903-A9 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20170008896-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-12 | — | — | US | disclosed |
| EP-3110845-A1 | COMPLEMENT FACTOR BB ANTIBODIES | ALLERGAN, INC. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-3107935-A2 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2016-12-28 | — | — | EP | disclosed |
| CN-106255689-A | Heteroaryl syk inhibitors | 勃林格殷格翰国际有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-106232624-A | Complement factor Bb antibodies | 阿勒根公司 | 2016-12-14 | — | — | CN | disclosed |
| EP-2518085-B1 | IL-17 receptor A antigen binding proteins | KIRIN-AMGEN INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9464048-B2 | 5-oxo-ETE receptor antagonist compounds | FLORIDA INSTITUTE OF TECHNOLOGY (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2016154749-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-10-06 | — | — | WO | disclosed |
| EP-2736886-B1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160256519-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RESEARCH INSTITUTE (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160251443-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
| EP-3054982-A1 | HYDROGEL-LINKED IL-1RA PRODRUG | Ascendis Pharma Osteoarthritis Division A/S (DK) | 2016-08-17 | — | — | EP | disclosed |
| US-20160208004-A1 | IL-17RA-IL-17RB Antagonists and Uses Thereof | AMGEN INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160159914-A1 | IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY | AMGEN INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-9328162-B2 | Therapeutic compositions for the treatment of dry eye disease | SCHEPENS EYE RESEARCH INSTITUTE (US) | 2016-05-03 | — | — | US | disclosed |
| CN-103889970-B | Piperidino-dihydrothienopyrimidine sulfoxides and their use in the treatment of COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-20 | — | — | CN | disclosed |
| CN-103827090-B | Substituted quinolines and their use as pharmaceuticals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-20 | — | — | CN | disclosed |
| US-20160002612-A1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2016-01-07 | — | — | US | disclosed |
| EP-2956476-A1 | LIGAND BINDING MOLECULES AND USES THEREOF | Vegenics Pty Limited (AU) | 2015-12-23 | — | — | EP | disclosed |
| EP-2748156-B1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-9199937-B2 | Substituted quinolines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| CN-104994854-A | Method for treating autoimmune, respiratory and/or inflammatory disorders by inhalation of roflumilast N-oxide | INCOZEN THERAPEUTICS PVT LTD | 2015-10-21 | — | — | CN | disclosed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-9150586-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| WO-2015140055-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140051-A1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140054-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015130826-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239987-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239966-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | XENCOR, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| WO-2015123715-A1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LIMITED (AU) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015127134-A2 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-9096673-B2 | IL-17 receptor A antigen binding proteins | KIRIN-AMGEN, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| CN-103214576-B | IL-17 receptor A antigen binding proteins | AMGEN INC | 2015-06-03 | — | — | CN | disclosed |
| US-20150148322-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| WO-2015052154-A1 | HYDROGEL-LINKED IL-1RA PRODRUG | ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S (DK) | 2015-04-16 | — | — | WO | disclosed |
| US-20150065489-A1 | Substituted Quinolines and Their Use As Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2015-03-05 | — | — | US | disclosed |
| EP-2076541-B1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | KIRIN AMGEN INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20150045376-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-8912173-B2 | Substituted quinolines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140356355-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| CN-104151428-A | IL-17RA-IL-17RB antagonists and uses thereof | AMGEN INC | 2014-11-19 | — | — | CN | disclosed |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-10-30 | — | — | US | disclosed |
| US-20140322238-A1 | IL-17RA-IL-17RB Antagonists and Uses Thereof | AMGEN INC. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2307456-B1 | ANG-2 INHIBITION TO TREAT MULTIPLE SCLEROSIS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2427430-B1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | UNIV MCGILL (CA) | 2014-09-10 | — | — | EP | disclosed |
| US-20140234330-A1 | IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014124487-A1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LIMITED (AU) | 2014-08-21 | — | — | WO | disclosed |
| US-8809382-B2 | 5-oxo-ETE receptor antagonist compounds | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-08-19 | — | — | US | disclosed |
| CN-101495513-B | Angiopoietin-2 specific binding agents | AMGEN INC | 2014-08-06 | — | — | CN | disclosed |
| US-8790648-B2 | Methods of treating psoriasis using IL-17 receptor A antibodies | AMGEN INC. (US) | 2014-07-29 | — | — | US | disclosed |
| CN-102037017-B | IL-17RA-IL-17RB antagonists and uses thereof | AMGEN INC | 2014-07-09 | — | — | CN | disclosed |
| EP-2748156-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | Boehringer Ingelheim International GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| CN-103889970-A | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use in the treatment of COPD and asthma | BOEHRINGER INGELHEIM INT | 2014-06-25 | — | — | CN | disclosed |
| US-8759326-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2736886-A1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2014-06-04 | — | — | EP | disclosed |
| CN-103827090-A | Substituted quinolines and their use as pharmaceuticals | BOEHRINGER INGELHEIM INT | 2014-05-28 | — | — | CN | disclosed |
| US-20140037635-A1 | METHODS OF TREATMENT USING IL-17E ANTAGONISTS | AMGEN INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| CN-101541833-B | Il-17 receptor a antigen binding proteins | KIRIN AMGEN INC | 2014-01-29 | — | — | CN | disclosed |
| US-8609670-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| EP-2671891-A2 | Ang-2 inhibition to treat multiple sclerosis | Amgen Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| EP-1294765-B1 | Use of an antibody specific for an IL-17 like polypeptide | AMGEN INC (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8592400-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20130302886-A1 | Pre-Ligand assembly domain of the IL-17 receptor | RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2013-11-14 | — | — | US | disclosed |
| CN-101657443-B | [1,2,3] triazole-substituted quinolines and coumarins as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD | 2013-10-23 | — | — | CN | disclosed |
| US-8545842-B2 | Polynucleotides encoding IL-17 receptor A antigen binding proteins | KIRIN-AMGEN, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| CN-103214576-A | IL-17 receptor A antigen binding proteins | AMGEN INC | 2013-07-24 | — | — | CN | disclosed |
| US-8460647-B2 | Pre-ligand assembly domain of the IL-17 receptor | AMGEN INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130142799-A1 | Angiopoietin-2 Specific Binding Agents | AMGEN, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8435518-B2 | Methods of using IL-17 receptor a antibodies | KIRIN-AMGEN, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20130079359-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| WO-2013026797-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| US-20130045927-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENSE EYE RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130029949-A1 | Substituted Quinolines and Their Use As Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014060-A1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013016220-A1 | IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY | AMGEN INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-20130004969-A1 | IL-17 Heteromeric Receptor Complex | AMGEN INC. (US) | 2013-01-03 | — | — | US | disclosed |
| EP-2538965-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | Schepens Eye Research Institute (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120308566-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | KIRIN-AMGEN, INC. | 2012-12-06 | — | — | US | disclosed |
| EP-2518085-A1 | IL-17 receptor A antigen binding proteins | Kirin-Amgen, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120251547-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2488552-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | Amgen Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2487188-A2 | IL-17 receptor A antigen binding proteins | Kirin-Amgen Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8242146-B2 | Administering ROFLUMILAS and DICLOFENAC; antiinflammatory agents | NYCOMED GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| EP-1869031-B1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK CANADA INC (CA) | 2012-08-08 | — | — | EP | disclosed |
| CN-102627638-A | Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor | MERCK FROSST CANADA LTD | 2012-08-08 | — | — | CN | disclosed |
| US-20120157666-A1 | INTERFERON-LIKE PROTEINS AND USES THEREOF | WELCHER ANDREW (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | FLORIDA INSTITUTE OF TECHNOLOGY | 2012-05-17 | — | — | US | disclosed |
| US-8148109-B2 | polypeptides and fusion proteins; for diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides | AMGEN INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2118093-B1 | [1,2,3]TRIAZOLYL SUBSTITUTED QUINOLINES AND COUMARINS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK CANADA INC (CA) | 2012-03-21 | — | — | EP | disclosed |
| EP-2427430-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2012-03-14 | — | — | EP | disclosed |
| US-8119128-B2 | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-02-21 | — | — | US | disclosed |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120028932-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120009190-A1 | IDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR | AMGEN INC. (NY) | 2012-01-12 | — | — | US | disclosed |
| EP-2400962-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2400961-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110311546-A1 | Angiopoietin-2 specific binding agents | AMGEN, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110274681-A1 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-1615952-B1 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011106697-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RESEARCH INSTITUTE (US) | 2011-09-01 | — | — | WO | disclosed |
| EP-2361262-A1 | TETRANECTIN TRIMERI ZING MODULE TRUNCATION VARIANTS | Anaphore, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7994291-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110166331-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110158978-A1 | ANG-2 INHIBITION TO TREAT MULTIPLE SCLEROSIS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-20110160438-A1 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7960409-B2 | e.g. 4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one; leukotriene biosynthesis and 5-lipoxygenase (5-LO); inhibitor; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-7943738-B2 | IL-17 receptor like molecules and uses thereof | AMGEN INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7939070-B2 | IL-17 receptor A antigen binding proteins | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| CN-102037017-A | IL-17RA-IL-17RB antagonists and uses thereof | AMGEN INC | 2011-04-27 | — | — | CN | disclosed |
| WO-2011046958-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2307456-A2 | ANG-2 INHIBITION TO TREAT MULTIPLE SCLEROSIS | Amgen Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110081339-A1 | METHODS OF USING IL-17 RECEPTOR A ANTIBODIES | AMGEN INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110052600-A1 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | AMGEN INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110008841-A1 | POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008356-A1 | IL-17 HETEROMERIC RECEPTOR COMPLEX | AMGEN, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100303820-A1 | METHODS OF TREATMENT USING IL-17E ANTAGONISTS | AMGEN INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100297668-A1 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY | AMGEN INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2250200-A2 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | AMGEN INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| CN-101889022-A | Trimeric IL-1Ra | ANAPHORE INC | 2010-11-17 | — | — | CN | disclosed |
| US-7833527-B2 | Using cytokine receptor specific immunoglobulin as therapeutic tool in treatment and prevention of inflammatory, nervous system, skin and autoimmune disorders | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010127452-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2010-11-11 | — | — | WO | disclosed |
| US-7811791-B2 | Interferon-like molecules and uses thereof | AMGEN INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7790674-B2 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010097332-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097334-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| US-7786284-B2 | Expression vector comprising nucleotide sequences coding cytokine receptor specific immunoglobulin for treatment and prevention of inflammation, cartilage degradation and bone resorption | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| CN-101810592-A | Contain the pharmaceutical preparation that is dispersed in the active matter in the substrate | ALTANA PHARMA AG | 2010-08-25 | — | — | CN | disclosed |
| US-7745586-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2195337-A1 | TRIMERIC IL-1RA | Anaphore, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7732587-B2 | Nucleic acids encoding truncated soluble tumor necrosis factor | AMGEN INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| CN-1802372-B | 7-[(1,3-thiazol-2-yl)thio]-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD | 2010-05-12 | — | — | CN | disclosed |
| WO-2010042243-A1 | TETRANECTIN TRIMERI ZING MODULE TRUNCATION VARIANTS | ANAPHORE, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-2170958-A1 | IL-17 HETEROMERIC RECEPTOR COMPLEX | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| CN-101657443-A | [1,2,3] triazole-substituted quinolines and coumarins as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD CA | 2010-02-24 | — | — | CN | disclosed |
| US-7666839-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666831-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666832-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7658924-B2 | Angiopoietin-2 specific binding agents | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20100028995-A1 | Tetranectin Trimerizing Polypeptides | ANAPHORE, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100028345-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2144928-A2 | JACQUELINIDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR | Amgen Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090325880-A1 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | AMGEN INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158432-A2 | ANG-2 INHIBITION TO TREAT MULTIPLE SCLEROSIS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-0904112-B1 | COMPOSITION COMPRISING IL-1RA AS INTERLEUKIN-1 INHIBITOR AND HYALURONAN AS CONTROLLED RELEASE POLYMER | AMGEN INC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090281287-A1 | IL-17 receptor like molecules and uses thereof | AMGEN INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009136976-A2 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | AMGEN INC (US) | 2009-11-12 | — | — | WO | disclosed |
| US-7611857-B2 | Identifying a modulator of IL-17 receptor-like polypeptide activity; drug screening; treating inflammation | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101541833-A | IL-17 receptor A antigen binding proteins | AMGEN INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-20090232799-A1 | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | disclosed |
| WO-2009105234-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DEFECTS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE OR PROTEIN | COMBINATORX, INCORPORATED (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20090203609-A1 | Use of IL-1 inhibitors for treating IL-1 mediated diseases | AMGEN INC. | 2009-08-13 | — | — | US | disclosed |
| US-7569387-B2 | Specifically binds an MK61 polypeptide produced by immunizing an animal | AMGEN INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090191212-A1 | Angiopoietin-2 Specific Binding Agents | AMGEN, INC. | 2009-07-30 | — | — | US | disclosed |
| CN-101495513-A | Angiopoietin-2 specific binding agents | AMGEN INC (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-2076541-A2 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | Amgen Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7553973-B2 | Pharmaceutical compounds | MERCK FROSST CANADA LTD. (CA) | 2009-06-30 | — | — | US | disclosed |
| US-20090143276-A1 | Trimeric IL-1Ra | ANAPHORE, INC. | 2009-06-04 | — | — | US | disclosed |
| EP-1317536-B1 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090098575-A1 | The Human E3alpha Ubiquitin Ligase Family | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009048961-A1 | TRIMERIC IL-1RA | ANAPHORE, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090074758-A1 | IL-17 receptor a antigen binding proteins | AMGEN, INC, (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | US | disclosed |
| US-20090048199-A1 | Hibernation-Related Genes and Proteins, Activators and Inhibitors Thereof and Methods of Use | HIBERNA CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090030048-A1 | Novel pharmaceutical compounds | BLOUIN MARC | 2009-01-29 | — | — | US | disclosed |
| WO-2008156709-A1 | IL-17 HETEROMERIC RECEPTOR COMPLEX | AMGEN INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-2002846-A2 | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases | Amgen Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| CN-101304737-A | Diaryl urea for treating diabetic neuropathy | BAYER HEALTHCARE AG (DE) | 2008-11-12 | — | — | CN | disclosed |
| CN-101304745-A | Diaryl ureas for the treatment of diabetic neuropathy | BAYER HEALTHCARE AG (DE) | 2008-11-12 | — | — | CN | disclosed |
| US-7449555-B2 | Antibodies of angiogenesis inhibiting domains CD148 | AMGEN INC. (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008131315-A2 | JACQUELINIDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008127813-A1 | HIBERNATION-RELATED GENES AND PROTEINS, ACTIVATORS AND INHIBITORS THEREOF AND METHODS OF USE | HIBERNA CORPORATION (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-20080255209-A1 | Combination of a NSAID and a PDE-4 inhibitor | NYCOMED GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080219979-A1 | Using cytokine receptor specific immunoglobulin as therapeutic tool in treatment and prevention of inflammatory, nervous system, skin and autoimmune disorders | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080220479-A1 | Expression vector comprising nucleotide sequences coding cytokine receptor specific immunoglobulin for treatment and prevention of inflammation, cartilage degradation and bone resorption | AMGEN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7422847-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2008095292-A1 | [1,2,3] TRIAZOLYL SUBSTITUTED QUINOLINES AND COUMARINS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188521-A1 | e.g. 4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one; leukotriene biosynthesis and 5-lipoxygenase (5-LO); inhibitor; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK CANADA INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| EP-1948172-A1 | DIARYL UREAS FOR TREATING DIABETIC NEUROPATHY | Bayer HealthCare AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1948144-A2 | DIARYL UREA FOR TREATING DIABETIC NEUROPATHY | Bayer HealthCare AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008054603-A9 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1933844-A1 | COMBINATION | Bayer HealthCare AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934205-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | Merck Frosst Canada Ltd. (CA) | 2008-06-25 | — | — | EP | disclosed |
| EP-1750764-A4 | ANTIBODIES OF ANGIOGENESIS INHIBITING DOMAINS OF CD148 | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008054603-A2 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1915369-A1 | NOVEL SUBSTITUTED 1,2,3-T II AZOLYLMETHYL-BENZOTHIOPHENE OR -INDOLE AND THEIR USE AS LEUKOTIIENE BIOSYNTHESIS INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-30 | — | — | EP | disclosed |
| CN-101146802-A | Thiadiazole-substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD (CA) | 2008-03-19 | — | — | CN | disclosed |
| CN-101124246-A | Antibodies to the angiogenesis inhibitory domain of CD148 | AMGEN INC (US) | 2008-02-13 | — | — | CN | disclosed |
| EP-1240327-B1 | INTERFERON-LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1869031-A1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | Merck Frosst Canada Ltd. (CA) | 2007-12-26 | — | — | EP | disclosed |
| US-20070231831-A1 | The human E3alpha ubiquitin ligase family | AMGEN INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070225221-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007095583-A2 | METHODS FOR TREATING CANCER AND SENSITIZING CANCER CELLS USING THE SERINE PROTEASE INHIBITOR, MASPIN | CHILDREN'S MEMORIAL RESEARCH CENTER (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-1814914-A2 | ANTIBODIES THAT BIND UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND EPITOPES THEREFOR | The Regents of the University of Colorado (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1805219-A1 | ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS | Amgen, Inc (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070149579-A1 | Novel pharmaceutical compounds | MERCK CANADA INC. (CA) | 2007-06-28 | — | — | US | disclosed |
| EP-0914431-B1 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I RECEPTORS | AMGEN INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070123459-A1 | IL-17 like molecules and uses thereof | AMGEN INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-7220547-B2 | Human E3α ubiquitin ligase family | AMGEN, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2007054302-A1 | DIARYL UREAS FOR TREATING DIABETIC NEUROPATHY | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054303-A2 | DIARYL UREA FOR TREATING DIABETIC NEUROPATHY | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-20070093418-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093419-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1777234-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7205275-B2 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2007039129-A1 | COMBINATION | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072801-A1 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1767544-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070065868-A1 | IL-17 receptor like molecules and uses thereof | AMGEN INC. (US) | 2007-03-22 | — | — | US | disclosed |
| EP-1764370-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7179625-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2007016784-A1 | NOVEL SUBSTITUTED 1,2,3-TΠAZOLYLMETHYL-BENZOTHIOPHENE OR -INDOLE AND THEIR USE AS LEUKOTΠENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-02-15 | — | — | WO | disclosed |
| EP-1750764-A2 | ANTIBODIES OF ANGIOGENESIS INHIBITING DOMAINS OF CD148 | Amgen Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20070015219-A1 | TNF receptor-like molecules and uses thereof | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| US-7153669-B2 | Nucleic acids encoding MK61 receptors | AMGEN INC. (US) | 2006-12-26 | — | — | US | disclosed |
| WO-2006099735-A1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK FROSST CANADA LTD. (CA) | 2006-09-28 | — | — | WO | disclosed |
| US-7094566-B2 | IL-17 receptor like molecules and uses thereof | AMGEN INC., (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | disclosed |
| CN-1802372-A | 7-[(1,3-thiazol-2-yl)thio]-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD (CA) | 2006-07-12 | — | — | CN | disclosed |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | GAREAU YVES | 2006-06-01 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006050177-A2 | ANTIBODIES THAT BIND UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND EPITOPES THEREFOR | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006045049-A1 | ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060078966-A1 | IL-17 receptor like polypeptides and uses thereof | AMGEN INC. (US) | 2006-04-13 | — | — | US | disclosed |
| US-20060078933-A1 | IL-receptor like molecules and uses thereof | AMGEN INC. (US) | 2006-04-13 | — | — | US | disclosed |
| US-20060078967-A1 | Antibodies for IL-17 receptor like polypeptides and uses thereof | AMGEN INC. (US) | 2006-04-13 | — | — | US | disclosed |
| EP-1636222-A1 | 7-[(1,3-THIAZOL-2-YL)THIO]-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| CN-1747731-A | Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders | ALTANA PHARMA AG (DE) | 2006-03-15 | — | — | CN | disclosed |
| US-20060034846-A1 | Use of TF antagonists | NOVO NORDISK A/S (DK) | 2006-02-16 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0971587-B1 | QUINOLINE LEUKOTRIENE ANTAGONISTS | MERCK & CO INC (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20060024795-A1 | Interferon-Like molecules and uses thereof | WELCHER ANDREW | 2006-02-02 | — | — | US | disclosed |
| US-20060024267-A1 | TNFr/OPG-like molecules and uses thereof | WELCHER ANDREW A | 2006-02-02 | — | — | US | disclosed |
| US-20060018909-A1 | Angiopoietin-2 specific binding agents | AMGEN INC. | 2006-01-26 | — | — | US | disclosed |
| US-6989147-B2 | Truncated soluble tumor necrosis factor type-I and type-II receptors | AMGEN INC. (US) | 2006-01-24 | — | — | US | disclosed |
| EP-1615952-A2 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | Amgen Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20060002931-A1 | Antibodies of angiogenesis inhibiting domains CD148 | AMGEN INC. (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2005117970-A2 | ANTIBODIES OF ANGIOGENESIS INHIBITING DOMAINS OF CD148 | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050250696-A1 | Truncated soluble tumor necrosis factor type-I and type-II receptors | FISHER ERIC F | 2005-11-10 | — | — | US | disclosed |
| US-20050234221-A1 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC., A DELAWARE CORP. | 2005-10-20 | — | — | US | disclosed |
| US-20050221344-A1 | Interferon-Like molecules and uses thereof | WELCHER ANDREW | 2005-10-06 | — | — | US | disclosed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050123512-A1 | Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof | AMGEN, INC., A CORPORATION OF THE STATE OF DELAWARE | 2005-06-09 | — | — | US | disclosed |
| US-20050089876-A1 | Human E3alpha ubiquitin ligase family | HAN HUI-QUAN (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050074427-A1 | IL-17 like molecules and uses thereof | MEDLOCK EUGENE (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050048029-A1 | Il-17 like molecules and uses thereof | AMGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-20050003451-A1 | IL-17 like molecules and uses thereof | MEDLOCK EUGENE (US) | 2005-01-06 | — | — | US | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| WO-2004108720-A1 | 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | WO | disclosed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004092215-A2 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040208872-A1 | Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof | AMGEN, INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-10-21 | — | — | US | disclosed |
| US-20040185037-A1 | Human E3alpha ubiquitin ligase family | HAN HUI-QUAN (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1456378-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | disclosed |
| CN-1523980-A | Pharmaceutical formulations containing an active dispersed in a matrix | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| EP-0971587-A4 | QUINOLINE LEUKOTRIENE ANTAGONISTS | MERCK & CO INC (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6733753-B2 | ANTIINFLAMMATORY PROTEIN | AMGEN INC. | 2004-05-11 | — | — | US | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-6706505-B1 | ISOLATED NUCLEIC ACID MOLECULE COMPRISING SPECIFIED NUCLEOTIDE SEQUENCE, NUCLEOTIDE SEQUENCE ENCODING SPECIFIED POLYPEPTIDE, OR NUCLEOTIDE SEQUENCE FULLY COMPLEMENTARY TO EITHER | AMGEN INC | 2004-03-16 | — | — | US | disclosed |
| US-20040047863-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | AMGEN INC. | 2004-03-11 | — | — | US | disclosed |
| US-20040048799-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | AMGEN INC. | 2004-03-11 | — | — | US | disclosed |
| US-20040048338-A1 | IL-17 receptor like molecules and uses thereof | JING SHUQIAN (US) | 2004-03-11 | — | — | US | disclosed |
| US-20040044001-A1 | Use of II-1 inhibitors for treating II-1 mediated diseases | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040023335-A1 | IL-17 like molecules and uses thereof | JING SHUQIAN (US) | 2004-02-05 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20030236193-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. | 2003-12-25 | — | — | US | disclosed |
| EP-0652874-B1 | 2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER LAMBERT CO (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1352656-A2 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | Amgen Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-20030166069-A1 | Interleukin-1 receptor antagonist-like molecules and uses thereof | AMGEN, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030166164-A1 | IL-17 like molecules and uses thereof | AMGEN INC. | 2003-09-04 | — | — | US | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| CN-1433431-A | Interleukin-1 receptor antagonist-like molecules and uses thereof | AMGEN INC (US) | 2003-07-30 | — | — | CN | disclosed |
| WO-2003055980-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2003-07-10 | — | — | WO | disclosed |
| US-20030124092-A1 | IL-17 like molecules and uses thereoflike molecules and uses thereof | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| EP-1317536-A2 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030099980-A1 | IL-17 receptor like molecules and uses thereof | JING SHUQIAN (US) | 2003-05-29 | — | — | US | disclosed |
| US-20030077246-A1 | TNFr/OPG-like molecules and uses thereof | WELCHER ANDREW A (US) | 2003-04-24 | — | — | US | disclosed |
| US-20030072756-A1 | Combination therapy using an IL-1 inhibitor and methotrexate | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| EP-1294765-A2 | IL-17 MOLECULES AND USES THEREOF | Amgen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20030054439-A1 | Truncated soluble tumor necrosis factor type-I and type-II receptors | AMGEN INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030004106-A1 | Interleukin-1 receptor antagonist-related molecules and uses thereof | AMGEN, INC., A CORPORATION OF THE STATE OF DELAWARE | 2003-01-02 | — | — | US | disclosed |
| WO-2001068859-A9 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1265924-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1266002-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1255837-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020150977-A1 | TNF receptor-like molecules and uses thereof | AMGEN INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1246844-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-RELATED MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020137137-A1 | Interferon-like molecules and uses thereof | AMGEN, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1239870-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240197-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240327-A2 | INTERFERON-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1238077-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020119924-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | AMGEN INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-20020045213-A1 | IL-17 receptor like molecules and uses thereof | AMGEN INC., A DELAWARE CORPORATION | 2002-04-18 | — | — | US | disclosed |
| US-20020037524-A1 | IL-17 like molecules and uses thereof | AMGEN INC., A DELAWARE CORPORATION | 2002-03-28 | — | — | US | disclosed |
| WO-2002020762-A2 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002008285-A2 | IL-17 MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-20020009454-A1 | Composition and method for treating inflammatory diseases | AMGEN INC. | 2002-01-24 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6306820-B1 | FAS ANTIGEN; RHEUMATIC DISEASES, ANTIINFLAMMATORY AGENTS; SEPTIC SHOCK PREVENTION | AMGEN INC. | 2001-10-23 | — | — | US | disclosed |
| US-6294170-B1 | PROTEINACEOUS IL-1 INHIBITOR (INTERLEUKIN-1RA) BY EXTENDED DELIVERY MEANS, E.G., CONTROLLED RELEASE POLYMER FORMULATIONS (HYALURONAN), IL-1RA FUSION PROTEINS AND CHEMICAL ATTACHMENT, AND CONTINUOUS PUMP INFUSION, ARTHRITIS, FUSION PROTEIN | AMGEN INC. | 2001-09-25 | — | — | US | disclosed |
| WO-2001068859-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068705-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001059120-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| WO-2001044472-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001042304-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-RELATED MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042305-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001041792-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042474-A2 | INTERFERON-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0788497-B1 | BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC (CA) | 2001-05-23 | — | — | EP | disclosed |
| US-6211209-B1 | NONDEGRADING TISSUES, DRUGS, DIPHENYLAMINES | WARNER-LAMBERT COMPANY | 2001-04-03 | — | — | US | disclosed |
| US-6096728-A | Composition and method for treating inflammatory diseases | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0788490-B1 | BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC (CA) | 2000-07-05 | — | — | EP | disclosed |
| EP-0604114-B1 | Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 2000-05-03 | — | — | EP | disclosed |
| EP-0971587-A1 | QUINOLINE LEUKOTRIENE ANTAGONISTS | Merck & Co., Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| CN-1240479-A | Truncated soluble tumor necrosis factor type-I and type-II receptors | AMGEN INC (US) | 2000-01-05 | — | — | CN | disclosed |
| EP-0949931-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0942740-A2 | COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES | AMGEN INC. (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5952347-A | 1-(((1-(3-(2-(7-CHLORO-2-QUINOLINYL)-ETHENYL)PHENYL)-(2-(2-HYD DROXY-2-PROPIONIC ACID)PHENYL)PROPYL)THIO)METHYL)-CYCLOPROPANE OR DERIVATIVE; ASTHMA; ANTIALLERGENS AND -INFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
| CN-1043761-C | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1999-06-23 | — | — | CN | disclosed |
| EP-0914431-A2 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS | AMGEN INC. (US) | 1999-05-12 | — | — | EP | disclosed |
| CN-1215340-A | Composition comprising interleukin-1 inhibitor and controlled release polymer | AMGEN BULDER INC (US) | 1999-04-28 | — | — | CN | disclosed |
| EP-0904112-A1 | COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER | Amgen Inc., (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5856322-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS | MERCK FROSST CANADA, INC. (CA) | 1999-01-05 | — | — | US | disclosed |
| WO-1998039970-A1 | QUINOLINE LEUKOTRIENE ANTAGONISTS | MERCK & CO., INC. (US) | 1998-09-17 | — | — | WO | disclosed |
| EP-0565185-B1 | Quinoline derivatives as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-07-08 | — | — | EP | disclosed |
| EP-0691972-B1 | FURO 3,2-b]PYRIDINES AND THIENO 3,2-b]PYRIDINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC (CA) | 1998-07-01 | — | — | EP | disclosed |
| WO-1998024463-A2 | COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024477-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0840728-A1 | HETEROARYL DIOL ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1998-05-13 | — | — | EP | disclosed |
| US-5750539-A | ANTIASTHMATICS | MERCK FROSST CANADA (CA) | 1998-05-12 | — | — | US | disclosed |
| EP-0480717-B1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998001555-A2 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS | AMGEN INC. (US) | 1998-01-15 | — | — | WO | disclosed |
| US-5703119-A | ANTIARTHRITIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1997028828-A1 | COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER | AMGEN BOULDER INC. (US) | 1997-08-14 | — | — | WO | disclosed |
| EP-0788497-A1 | BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1997-08-13 | — | — | EP | disclosed |
| EP-0788490-A1 | BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1997-08-13 | — | — | EP | disclosed |
| EP-0500360-B1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-06-25 | — | — | EP | disclosed |
| CN-1148389-A | Diaryl 5, 6-fused heterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-04-23 | — | — | CN | disclosed |
| WO-1996040638-A1 | HETEROARYL DIOL ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5576338-A | ANTIALLERGENS, ANTIHISTAMINES, ANTIINFLAMMATORY AGENTS AND CYTOPROTECTIVE AGENTS FOR CARDIOVASCULAR DISORDERS | MERCK FROSST CANADA, INC. (CA) | 1996-11-19 | — | — | US | disclosed |
| EP-0737196-A1 | DIARYL 5,6-FUSED HETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1996-10-16 | — | — | EP | disclosed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| US-5552437-A | ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY, AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-09-03 | — | — | US | disclosed |
| US-5527827-A | ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-06-18 | — | — | US | disclosed |
| WO-1996013491-A1 | BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1996-05-09 | — | — | WO | disclosed |
| WO-1996013500-A1 | BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1996-05-09 | — | — | WO | disclosed |
| EP-0535925-B1 | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC (CA) | 1996-04-24 | — | — | EP | disclosed |
| US-5506227-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-04-09 | — | — | US | disclosed |
| EP-0699188-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1996-03-06 | — | — | EP | disclosed |
| US-5494927-A | INHIBITS ACTIVITY OF 5-LIPOXYGENASE AND-OR CYCLOOXYGENASE | WARNER-LAMBERT COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0449216-B1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER LAMBERT CO (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0691972-A1 | FURO 3,2-b]PYRIDINES AND THIENO 3,2-b]PYRIDINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1996-01-17 | — | — | EP | disclosed |
| US-5472964-A | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1995-12-05 | — | — | US | disclosed |
| US-5464856-A | Arylmethylenyl derivatives of imidazolidinones useful as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| US-5462952-A | Have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| US-5459271-A | Arylbicyclooctanes as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1995-10-17 | — | — | US | disclosed |
| EP-0480708-B1 | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1995-10-11 | — | — | EP | disclosed |
| EP-0371438-B1 | 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents | WARNER LAMBERT CO (US) | 1995-08-30 | — | — | EP | disclosed |
| US-5442111-A | Antiinflammatory agent, antiallergens | WARNER-LAMBERT COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5438141-A | Antiasthmatic agents, antiallergens | MERCK FROSST CANADA, INC. (CA) | 1995-08-01 | — | — | US | disclosed |
| US-5432181-A | Substituted heteroaryl analogs of 4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1995-07-11 | — | — | US | disclosed |
| WO-1995018132-A1 | DIARYL 5,6-FUSED HETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1995-07-06 | — | — | WO | disclosed |
| US-5428060-A | Useful as antiasthamatic, antiallergic, antiinflammatory and cytoprotective agent | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| US-5428033-A | Useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotecyive agents | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| US-5426109-A | Leukotriene biosynthesis inhibitors; antiinflammatory, cytoprotective agents, antiallergens | MERCK FROSST CANADA, INC. (CA) | 1995-06-20 | — | — | US | disclosed |
| US-5424320-A | Antihistamine, antiallergic, antiinflammatory and cytoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1995-06-13 | — | — | US | disclosed |
| EP-0652874-A1 | 2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1995-05-17 | — | — | EP | disclosed |
| US-5410054-A | Heteroaryl quinolines as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1995-04-25 | — | — | US | disclosed |
| EP-0419049-B1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC (CA) | 1995-04-12 | — | — | EP | disclosed |
| US-5393923-A | Enzyme inhibitor; treating arthritis and inflammation | WARNER-LAMBERT COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0639181-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1995-02-22 | — | — | EP | disclosed |
| US-5389650-A | Antiinflammatory agents, anticoagulants, antispasmodic agents | MERCK FROSST CANADA, INC. (CA) | 1995-02-14 | — | — | US | disclosed |
| WO-1995003309-A1 | ARYLBICYCLOOCTANES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995003300-A1 | HETEROARYL QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1995-02-02 | — | — | WO | disclosed |
| US-5380850-A | Quinoline hydrazine intermediates | MERCK FROSST CANADA, INC. (CA) | 1995-01-10 | — | — | US | disclosed |
| US-5376670-A | 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1994-12-27 | — | — | US | disclosed |
| US-5374635-A | Antiinflammatory agents, lipoxygenase inhibitor, antiallergens , cytoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1994-12-20 | — | — | US | disclosed |
| WO-1994027968-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-12-08 | — | — | WO | disclosed |
| US-5360815-A | Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1994-11-01 | — | — | US | disclosed |
| US-5358964-A | Antiarthritic agents | WARNER-LAMBERT COMPANY (US) | 1994-10-25 | — | — | US | disclosed |
| US-5356898-A | Antiinflammatory agents, antiallergens, antiulcer agents | WARNER-LAMBERT COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1994022869-A1 | FURO[3,2-b]PYRIDINES AND THIENO[3,2-b]PYRIDINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-10-13 | — | — | WO | disclosed |
| US-5350744-A | Antiinflammatory, antiallergen | MERCK FROSST CANADA, INC. (CA) | 1994-09-27 | — | — | US | disclosed |
| US-5350760-A | Aza-5,5-fused hetrocyclic acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1994-09-27 | — | — | US | disclosed |
| US-5348957-A | Gastrointestinal ulcer treatment | WARNER-LAMBERT COMPANY (US) | 1994-09-20 | — | — | US | disclosed |
| US-5340815-A | Inhibitors of 5-lipoxygenase and/or cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| US-5334597-A | Anti-asthmatic, antiallergic, antiinflammatory, cytoprotective treats angina, cerebral spasm, nephritis, hepatitis, uveitis, endotoxemia and allograft rejection | MERCK FROSST CANADA, INC. (CA) | 1994-08-02 | — | — | US | disclosed |
| US-5334719-A | Antihistamines, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1994-08-02 | — | — | US | disclosed |
| WO-1994014815-A1 | DIARYL 5,6-FUSEDHETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-07-07 | — | — | WO | disclosed |
| EP-0604114-A1 | Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1994-06-29 | — | — | EP | disclosed |
| WO-1994013662-A1 | (AZAARYLMETHOXY)INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-06-23 | — | — | WO | disclosed |
| WO-1994013293-A2 | (QUINOLIN-2-YLMETHOXY)INDOLES AS INHIBITORS OF THE BIOSYNTHESIS OF LEUKOTRIENES | MERCK FROSST CANADA INC. (CA) | 1994-06-23 | — | — | WO | disclosed |
| CN-1087907-A | Heteroaryl naphthalene as white (cell) triolefin biosynthesis inhibitor | MERCK FROSST CANADA INC (CA) | 1994-06-15 | — | — | CN | disclosed |
| WO-1994011378-A1 | ARYL THIOPYRANO[2,3,4-c,d]INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-05-26 | — | — | WO | disclosed |
| US-5314900-A | Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1994-05-24 | — | — | US | disclosed |
| US-5314898-A | Inhibitors of 5-lipoxygenase | MERCK & CO., INC. (US) | 1994-05-24 | — | — | US | disclosed |
| US-5312821-A | Antiulcer agents | WARNER-LAMBERT COMPANY (US) | 1994-05-17 | — | — | US | disclosed |
| US-5308850-A | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1994-05-03 | — | — | US | disclosed |
| US-5308852-A | Cardiovascular disorders | MERCK FROSST CANADA, INC. (CA) | 1994-05-03 | — | — | US | disclosed |
| US-5306822-A | Mono-, di- or tri-methoxyphenylmethylene-2-thioxo-4-oxazolidinone as antihistamines | WARNER-LAMBERT COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| US-5302597-A | Enzyme inhibitors | WARNER-LAMBERT COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| EP-0343643-B1 | Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents | WARNER LAMBERT CO (US) | 1994-03-23 | — | — | EP | disclosed |
| WO-1994005657-A1 | HETEROARYLNAPHTHALENE HYDROXY ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994005658-A1 | HETEROARYLNAPHTHALENE LACTONES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994005656-A1 | PHENYLNAPHTHALENE LACTONES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994005653-A1 | PHENYLNAPHTHALENE HYDROXY ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-03-17 | — | — | WO | disclosed |
| CN-1083052-A | Fluorine-containing hydroxyalkylquinolinacids acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1994-03-02 | — | — | CN | disclosed |
| US-5290798-A | Antihistamines, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1994-03-01 | — | — | US | disclosed |
| US-5290800-A | Enzyme inhibitors | WARNER-LAMBERT COMPANY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5288896-A | 3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor | WARNER-LAMBERT COMPANY (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1994003448-A1 | 2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5284949-A | 2-substituted amino-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| US-5281720-A | Antiasthmatics, antiallergens, antiinflammatory agents and cytoprotective agents | MERCK FROSST CANADA, INC. | 1994-01-25 | — | — | US | disclosed |
| EP-0579304-A1 | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1994-01-19 | — | — | EP | disclosed |
| WO-1994000444-A1 | HETEROARYLNAPHTHALENES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000446-A1 | FLUORINATED QUINOLINE INDOLES AS INHIBITORS OF THE BIOSYNTHESIS OF LEUKOTRIENES | MERCK FROSST CANADA INC. (CA) | 1994-01-06 | — | — | WO | disclosed |
| US-5273980-A | Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1993-12-28 | — | — | US | disclosed |
| WO-1993025546-A1 | BICYCLIC(AZAAROMATIC)INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1993-12-23 | — | — | WO | disclosed |
| US-5272145-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-12-21 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5270319-A | 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-12-14 | — | — | US | disclosed |
| US-5266568-A | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-11-30 | — | — | US | disclosed |
| EP-0569491-A4 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0569493-A4 | SUBSTITUTED 4,6-DI-TERTIARY-BUTYL-5-HYDROXY-PYRIMIDINES | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0569491-A1 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-11-18 | — | — | EP | disclosed |
| EP-0569493-A1 | SUBSTITUTED 4,6-DI-TERTIARY-BUTYL-5-HYDROXY-PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1993-11-18 | — | — | EP | disclosed |
| WO-1993021169-A1 | BENZOTHIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021168-A1 | THIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021159-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021158-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| EP-0384594-B1 | Anti-inflammatory aryl derivatives | WELLCOME FOUND (GB) | 1993-10-27 | — | — | EP | disclosed |
| US-5256680-A | 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0565135-A1 | Known and selected novel arylmethylenyl derivatives of imidazolidinones useful as antiallergy agents and antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-10-13 | — | — | EP | disclosed |
| EP-0565185-A1 | Quinoline derivatives as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1993-10-13 | — | — | EP | disclosed |
| US-5252585-A | Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-10-12 | — | — | US | disclosed |
| US-5252599-A | Antiasthma, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-10-12 | — | — | US | disclosed |
| US-5250552-A | 3-[thiazolidinone, oxazolidinone, imidazolidinone]-indoles as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5248682-A | Inhibitors of lipoxygenase and cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| EP-0241043-B1 | NOVEL DIARYLALKANOIDS HAVING ACTIVITY AS LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-09-01 | — | — | EP | disclosed |
| US-5240929-A | Lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1993-08-31 | — | — | US | disclosed |
| WO-1993016069-A1 | (AZAAROMATICALKOXY)INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1993-08-19 | — | — | WO | disclosed |
| US-5234937-A | 3,5-di-tertiary-butyl-4-hydroxphenyl oxazolyl methanones and related compounds as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| US-5234939-A | 3,5-di-tertiary-butyl-4-hydroxyphenyl imidazolyl methanones and related compounds as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| US-5232916-A | Inhibitors of leukotriene synthesis | MERCK FROSST CANADA, INC. (CA) | 1993-08-03 | — | — | US | disclosed |
| US-5227399-A | Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1993-07-13 | — | — | US | disclosed |
| US-5221678-A | Cardiovascular disorders, antiinflammatory agents, antiallergens | MERCK FROSST CANADA, INC. (CA) | 1993-06-22 | — | — | US | disclosed |
| US-5220025-A | 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| US-5215986-A | 5-hydroxy-2-pyrimidinylmethylene oxaza heterocycles | WARNER-LAMBERT COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5212189-A | Enzyme inhibitors | WARNER-LAMBERT COMPANY (US) | 1993-05-18 | — | — | US | disclosed |
| US-5212180-A | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-05-18 | — | — | US | disclosed |
| US-5208251-A | Compounds for antiinflammatory agents, antiallergens, antiarthritic, antiulcer agents | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| US-5208250-A | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0538000-A1 | Indole and indazole carbamates as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-04-21 | — | — | EP | disclosed |
| US-5204344-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| US-5202321-A | Antihistamine, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-04-13 | — | — | US | disclosed |
| EP-0535924-A1 | (Bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1993-04-07 | — | — | EP | disclosed |
| EP-0535923-A1 | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1993-04-07 | — | — | EP | disclosed |
| EP-0535926-A1 | (Hetero-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1993-04-07 | — | — | EP | disclosed |
| EP-0535925-A1 | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1993-04-07 | — | — | EP | disclosed |
| US-5196431-A | 2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| WO-1993005039-A1 | 5-HYDROXY-2-PYRIMIDINYLMETHYLENE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-03-18 | — | — | WO | disclosed |
| US-5190968-A | Antiinflammatory | MERCK FROSST CANADA, INC. (CA) | 1993-03-02 | — | — | US | disclosed |
| US-5187175-A | 2-carbonyl substituted-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| US-5187180-A | Asthma; eye inflamation | MERCK FROSST CANADA, INC. (CA) | 1993-02-16 | — | — | US | disclosed |
| US-5177079-A | Antiallergen, antiulcer | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| US-5177259-A | Diarylalkanoids having activity as lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
| US-5155122-A | Cyclooxygenase, lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| CN-1065062-A | Quinoline-containing ketoacids as leukotriene antagonist | MERCK FROSST CANADA INC (CA) | 1992-10-07 | — | — | CN | disclosed |
| US-5149703-A | Anti-asthma, allergen and inflammatory agents, cyctoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1992-09-22 | — | — | US | disclosed |
| EP-0501579-A1 | Naphthalene lactones as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-09-02 | — | — | EP | disclosed |
| EP-0501578-A1 | Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-09-02 | — | — | EP | disclosed |
| US-5143929-A | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| US-5143928-A | Inhibitors of cyclooxygenase and lipoxygenase | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| US-5143927-A | Antiallergens; lipoxygenase and cyclooxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0500360-A1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-08-26 | — | — | EP | disclosed |
| US-5142095-A | Treating inflammation, allergies, asthma, cardiovascular disorders, psoriasis | WARNER-LAMBERT COMPANY (US) | 1992-08-25 | — | — | US | disclosed |
| WO-1992013844-A1 | SUBSTITUTED 4,6-DI-TERTIARY-BUTYL-5-HYDROXY-PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992013536-A1 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5135940-A | Antiallegens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1992-08-04 | — | — | US | disclosed |
| US-5132319-A | Antiasthmatic, antiinflammatory, antiallergen and cytoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1992-07-21 | — | — | US | disclosed |
| US-5128364-A | Antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1992-07-07 | — | — | US | disclosed |
| US-5124347-A | Inhibits 5-lipoxygenase and cyclooxygenase; for treatment of allergies, arthritis, pain | WARNER-LAMBERT CO. (US) | 1992-06-23 | — | — | US | disclosed |
| CN-1061594-A | Hydroxyalkyl quinoline ether acid as leukotriene antagonists | MERCK FROSST CANADA INT (CA) | 1992-06-03 | — | — | CN | disclosed |
| CN-1061408-A | Saturated hydroxyalkyl quinolinic acids as leukotriene antagonists | MERCK FROSST CANADA INC (US) | 1992-05-27 | — | — | CN | disclosed |
| US-5114958-A | Lipoxygenase or cyclooxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1992-05-19 | — | — | US | disclosed |
| US-5112846-A | Nonsteroidal antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0480708-A2 | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| US-5102897-A | Antiinflammatory, antiarthritic, antiulcer or antiischemic agents | WARNER-LAMBERT COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| US-5102881-A | Leukotriene biosynthesis inhibitor | MERCK FROSST CANADA, INC. (CA) | 1992-04-07 | — | — | US | disclosed |
| US-5093356-A | Antiallergens, antiasthma, antiinflammatory, cytoprotective | MERCK FROSST CANADA, INC. (CA) | 1992-03-03 | — | — | US | disclosed |
| US-5087638-A | Inhibitors of mammalian leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1992-02-11 | — | — | US | disclosed |
| US-5086064-A | Inhibitor of 5-lipoxygenase, cycloxygenanse and/or both | WARNER-LAMBERT COMPANY (US) | 1992-02-04 | — | — | US | disclosed |
| EP-0468785-A2 | (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1992-01-29 | — | — | EP | disclosed |
| EP-0468789-A2 | (Quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1992-01-29 | — | — | EP | disclosed |
| US-5081145-A | Contractile prostaglandin antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-01-14 | — | — | US | disclosed |
| US-5077411-A | Antiallergens, antiinflammatory agents; cardiovascular disorders, migraines, psoriasis | WARNER-LAMBERT CO. (US) | 1991-12-31 | — | — | US | disclosed |
| US-5075330-A | N-hydroxyamide, N-hydroxythioamide, N-hydroxyurea, and N-hydroxythiourea derivatives of selected NSAIDS as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-12-24 | — | — | US | disclosed |
| US-5066668-A | Enzyme inhibitors, cyclooxygenase and lipoxygenase, mixture with nonsteroid antiinflammatory agent | WARNER-LAMBERT CO. (US) | 1991-11-19 | — | — | US | disclosed |
| CN-1055180-A | 3 of thiazolinone, azoles quinoline ketone and the imidazolone type that 2-replaces, the preparation method of 5-di-tert-butyl-hydroxy phenyl methylene derivatives | WARNER LAMBERT CO (US) | 1991-10-09 | — | — | CN | disclosed |
| EP-0449216-A1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0449211-A1 | 3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0449223-A1 | 3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxa-zolyl, and imidazolyl methanones and related compounds as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5036067-A | Enzyme inhibotors | MERCK & CO., INC. (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0138481-B1 | LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1991-06-26 | — | — | EP | disclosed |
| US-5017583-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1991-05-21 | — | — | US | disclosed |
| EP-0140709-B1 | 5-LIPOXYGENASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1991-04-03 | — | — | EP | disclosed |
| EP-0419049-A1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1991-03-27 | — | — | EP | disclosed |
| EP-0245825-B1 | STYRYL PYRAZOLES, ISOXAZOLES AND ANALOGS THEREOF HAVING ACTIVITY AS 5-LIPOXY-GENASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
| US-4983628-A | ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1991-01-08 | — | — | US | disclosed |
| US-4981865-A | N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0401857-A2 | Fenamate 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0174770-B1 | LEUKOTRIENE ANTAGONISTS, THEIR PREPARATION, USE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF MAKING THEM | MERCK FROSST CANADA INC. (CA) | 1990-10-24 | — | — | EP | disclosed |
| US-4962119-A | Inhibit lipoxygenase, cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
| US-4959503-A | Diarylalkanoids having activity as lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0384594-A1 | Anti-inflammatory aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-08-29 | — | — | EP | disclosed |
| EP-0140684-B1 | LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1990-07-11 | — | — | EP | disclosed |
| US-4939145-A | Phenothiazone derivatives and analogs | MERCK FROSST CANADA, INC. (CA) | 1990-07-03 | — | — | US | disclosed |
| EP-0371438-A2 | 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4924002-A | REACTION WITH MOLYBDENUM CARBONYL AND HYDRAZINE | WARNER-LAMBERT COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| US-4912131-A | 4,7-diacyloxybenzofuran derivatives | MERCK FROSST CANADA, INC. (CA) | 1990-03-27 | — | — | US | disclosed |
| WO-1990001929-A1 | NEW MEDICAL USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-03-08 | — | — | WO | disclosed |
| EP-0349062-A1 | Quinoline ether alkanoic acid | MERCK FROSST CANADA INC. (CA) | 1990-01-03 | — | — | EP | disclosed |
| EP-0343643-A2 | Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents | WARNER-LAMBERT COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
| EP-0166591-B1 | INDOLE-2-ALKANOIC ACIDS AND THEIR USE AS PROSTAGLANDIN ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1989-11-23 | — | — | EP | disclosed |
| EP-0342682-A2 | Hydroxamate derivatives of selected nonsteroidal anti-inflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition | WARNER-LAMBERT COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
| US-4877881-A | SUNSCREEN | WARNER-LAMBERT COMPANY (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0338782-A1 | Benzofuran derivatives | MERCK FROSST CANADA INC. (CA) | 1989-10-25 | — | — | EP | disclosed |
| US-4876246-A | Benzo[a]phenothiazines and hydro-derivatives for inhibiting leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1989-10-24 | — | — | US | disclosed |
| US-4871756-A | ANTIASTHMATICS, ANTIALLERGENS, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA, INC. (CA) | 1989-10-03 | — | — | US | disclosed |
| US-4863958-A | TREATING ALLERGIC CONDITIONS, ASTHMA, CARDIOVASCULAR DISORDERS, AND INFLAMMATION | MERCK FROSST CANADA, INC. (CA) | 1989-09-05 | — | — | US | disclosed |
| EP-0165810-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES, THEIR USE IN INHIBITING MAMMALIAN LEUKOTRIENE BIOSYNTHESIS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES | MERCK FROSST CANADA INC. (CA) | 1989-08-23 | — | — | EP | disclosed |
| EP-0136893-B1 | Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them | MERCK FROSST CANADA INC. (CA) | 1989-08-16 | — | — | EP | disclosed |
| US-4845108-A | ANTISTHMA, ANTIALLERGIC, ANTIINFLAMMATORY | MERCK FROSST CANADA, INC. (CA) | 1989-07-04 | — | — | US | disclosed |
| US-4845083-A | PHENOTHIAZINE DERIVATIVES AND ANALOGS | MERCK FROSST CANADA, INC. (CA) | 1989-07-04 | — | — | US | disclosed |
| US-4820867-A | ANTIALLERGENS | MERCK FROSST CANADA, INC. (CA) | 1989-04-11 | — | — | US | disclosed |
| US-4810716-A | ANTIINFLAMMATORY, ANTIALLERGY, ANTIISCHEMIC | WARNER-LAMBERT COMPANY (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0200443-B1 | LIPOXYGENASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1989-03-01 | — | — | EP | disclosed |
| EP-0301692-A2 | 4,7-Benzofurandione derivatives | MERCK FROSST CANADA INC. (CA) | 1989-02-01 | — | — | EP | disclosed |
| US-4800228-A | INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA, INC. (CA) | 1989-01-24 | — | — | US | disclosed |
| EP-0295851-A1 | 4,7-diacyloxybenzofuran derivatives | MERCK FROSST CANADA INC. (CA) | 1988-12-21 | — | — | EP | disclosed |
| US-4778805-A | ANTIALLERGENS, CARDIOVASCULAR DISORDERS, ANTIINFLAMMATORY AGENTS, SKIN AND VISION DISORDERS | MERCK FROSST CANADA (CA) | 1988-10-18 | — | — | US | disclosed |
| US-4761425-A | ANTIASTHMATICS; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1988-08-02 | — | — | US | disclosed |
| US-4728735-A | LIPOXYGENASE INHIBITORS | MERCK & CO., INC. (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0123543-B1 | LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION AND USE AND COMPOSITIONS CONTAINING THEM | MERCK FROSST CANADA INC. (CA) | 1988-02-03 | — | — | EP | disclosed |
| US-4720505-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1988-01-19 | — | — | US | disclosed |
| EP-0252639-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1988-01-13 | — | — | EP | disclosed |
| US-4717736-A | LEUKOTRIENES, GASTRIC CYTOPROTECTION, AMIDO ACIDS AND ESTERS | MERCK FROSST CANADA, INC. (CA) | 1988-01-05 | — | — | US | disclosed |
| EP-0245825-A1 | Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them | WARNER-LAMBERT COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
| EP-0241043-A2 | Novel diarylalkanoids having activity as lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1987-10-14 | — | — | EP | disclosed |
| EP-0150118-B1 | ANTAGONISTS OF SLOW REACTING SUBSTANCES OF ANAPHYLAXIS | MERCK FROSST CANADA INC. (CA) | 1987-09-16 | — | — | EP | disclosed |
| US-4683325-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS | MERCK FROSST CANADA, INC. (CA) | 1987-07-28 | — | — | US | disclosed |
| EP-0123541-B1 | LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1987-07-22 | — | — | EP | disclosed |
| US-4663347-A | ANTIINFLAMMATORY, ANTIALLERGENS, CARDIOVASCULAR | MERCK FROSST CANADA, INC. (CA) | 1987-05-05 | — | — | US | disclosed |
| US-4634766-A | LIPOXYGENASE INHIBITORS | MERCK FROSST CANADA, INC. (CA) | 1987-01-06 | — | — | US | disclosed |
| EP-0200443-A1 | Lipoxygenase inhibitors | MERCK FROSST CANADA INC. (CA) | 1986-11-05 | — | — | EP | disclosed |
| US-4617407-A | ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1986-10-14 | — | — | US | disclosed |
| US-4611056-A | Benzo[A]phenothiazines and hydro-derivatives | MERCK FROSST CANADA, INC. (CA) | 1986-09-09 | — | — | US | disclosed |
| US-4609744-A | 4-oxo-benzopyran carboxylic acids | MERCK FROSST CANADA INC. (CA) | 1986-09-02 | — | — | US | disclosed |
| EP-0174770-A1 | Leukotriene antagonists, their preparation, use pharmaceutical compositions containing them and methods of making them | MERCK FROSST CANADA INC. (CA) | 1986-03-19 | — | — | EP | disclosed |
| EP-0166591-A2 | Indole-2-alkanoic acids and their use as prostaglandin antagonists | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | disclosed |
| EP-0165810-A2 | Benzofuran and benzothiophene derivatives, their use in inhibiting mammalian leukotriene biosynthesis, and pharmaceutical compositions containing these derivatives | MERCK FROSST CANADA INC. (CA) | 1985-12-27 | — | — | EP | disclosed |
| EP-0156233-A2 | Use of leukotriene antagonists for producing cytoprotective pharmaceutical compositions and process for producing cytoprotective pharmaceutical compositions | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0155623-A2 | Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition | MERCK & CO. INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0150118-A2 | Antagonists of slow reacting substances of anaphylaxis | MERCK FROSST CANADA INC. (CA) | 1985-07-31 | — | — | EP | disclosed |
| EP-0147217-A2 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1985-07-03 | — | — | EP | disclosed |
| EP-0146243-A1 | Lipoxygenase inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-06-26 | — | — | EP | disclosed |
| EP-0140709-A2 | 5-Lipoxygenase inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-05-08 | — | — | EP | disclosed |
| EP-0140684-A2 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1985-05-08 | — | — | EP | disclosed |
| EP-0138481-A2 | Leukotriene biosynthesis inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-04-24 | — | — | EP | disclosed |
| EP-0136893-A2 | Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them | MERCK FROSST CANADA INC. (CA) | 1985-04-10 | — | — | EP | disclosed |
| EP-0123543-A1 | Leukotriene antagonists, their production and use and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
| EP-0123541-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
| US-4285962-A | ADMINISTERING 2-METHYL-5-METHOXY-INDOL-3-YLACETOHYDROXAMIC ACID | ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.P.A. (IT) | 1981-08-25 | — | — | US | disclosed |
| US-4285962-A | ADMINISTERING 2-METHYL-5-METHOXY-INDOL-3-YLACETOHYDROXAMIC ACID | ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.P.A. (IT) | 1981-08-25 | — | — | US | disclosed |
| US-4186133-A | Process for the preparation of an indole-3-acetohydroxamic acid | ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.P.A. (IT) | 1980-01-29 | — | — | US | disclosed |
| US-4186133-A | Process for the preparation of an indole-3-acetohydroxamic acid | ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.P.A. (IT) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | IL17A, IL2, IL18 | AKR1C2 549/4885MTNR1A 1211/4885MTNR1B 1161/4885 |
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | AKR1C2 672/4885MTNR1A 1682/4885MTNR1B 1333/4885 |
| US-20250206742-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | AKR1C2 2234/4885MTNR1A 908/4885MTNR1B 1227/4885 |
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | AKR1C2 4629/4885MTNR1A 4491/4885MTNR1B 4642/4885 |
| US-20160256519-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | AKR1C2 2843/4885MTNR1A 732/4885MTNR1B 858/4885 |
| US-12157737-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | AKR1C2 127/4885MTNR1A 1311/4885MTNR1B 1081/4885 |
| US-20110166331-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL2RA | AKR1C2 1696/4885MTNR1A 1445/4885MTNR1B 2011/4885 |
| US-20250276957-A1 | CRYSTALLINE FORMS OF AN IL-17 INHIBITOR | IL17A, IL2, IL23R | AKR1C2 2661/4885MTNR1A 4694/4885MTNR1B 4611/4885 |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | AKR1C2 127/4885MTNR1A 1311/4885MTNR1B 1081/4885 |
| US-20180072754-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | AKR1C2 672/4885MTNR1A 1682/4885MTNR1B 1333/4885 |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | AKR1C2 905/4885MTNR1A 287/4885MTNR1B 250/4885 |
| US-20120308566-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL23R, IL15RA, IL2RA | AKR1C2 2688/4885MTNR1A 1763/4885MTNR1B 2211/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | AKR1C2 956/4885MTNR1A 486/4885MTNR1B 763/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | AKR1C2 751/4885MTNR1A 1974/4885MTNR1B 1701/4885 |
| US-20130079359-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, SQOR, TST | AKR1C2 548/4885MTNR1A 1371/4885MTNR1B 1388/4885 |
| US-11274078-B2 | Drug for treating tumor diseases and having antibacterial antivirus anti-inflammatory effects | NFKBIA, TNF, CHUK | AKR1C2 1415/4885MTNR1A 3524/4885MTNR1B 4500/4885 |
| US-20040044001-A1 | Use of II-1 inhibitors for treating II-1 mediated diseases | IL1A, IL1B, IL1R1 | AKR1C2 817/4885MTNR1A 80/4885MTNR1B 85/4885 |
| US-20100028345-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | AKR1C2 2090/4885MTNR1A 1139/4885MTNR1B 2016/4885 |
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | AKR1C2 2843/4885MTNR1A 732/4885MTNR1B 858/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | AKR1C2 4507/4885MTNR1A 3457/4885MTNR1B 3685/4885 |
| US-20240067627-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | AKR1C2 795/4885MTNR1A 424/4885MTNR1B 713/4885 |
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | AKR1C2 127/4885MTNR1A 1311/4885MTNR1B 1081/4885 |
| US-20090203609-A1 | Use of IL-1 inhibitors for treating IL-1 mediated diseases | IL1A, IL1B, IL1R1 | AKR1C2 811/4885MTNR1A 115/4885MTNR1B 188/4885 |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | HTR5A, EDNRA, HTR3E | AKR1C2 779/4885MTNR1A 47/4885MTNR1B 62/4885 |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | HRH4, HRH3, HRH1 | AKR1C2 472/4885MTNR1A 334/4885MTNR1B 414/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | AKR1C2 1789/4885MTNR1A 139/4885MTNR1B 272/4885 |
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | AKR1C2 1217/4885MTNR1A 921/4885MTNR1B 1578/4885 |
| US-20040048799-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | TNF, TNFRSF1A, TNFSF11 | AKR1C2 3000/4885MTNR1A 644/4885MTNR1B 444/4885 |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PTGER4, PDE4A, PDE12 | AKR1C2 1425/4885MTNR1A 472/4885MTNR1B 464/4885 |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | AKR1C2 956/4885MTNR1A 486/4885MTNR1B 763/4885 |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | AKR1C2 652/4885MTNR1A 358/4885MTNR1B 427/4885 |
| US-20080188521-A1 | e.g. 4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one; leukotriene biosynthesis and 5-lipoxygenase (5-LO); inhibitor; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | ALOX5, ALOX15, ALOX15B | AKR1C2 659/4885MTNR1A 199/4885MTNR1B 278/4885 |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | AKR1C2 905/4885MTNR1A 287/4885MTNR1B 250/4885 |
| US-10208122-B2 | IL-17 receptor A antigen binding proteins | IL17A, IL2RA, IL23R | AKR1C2 2455/4885MTNR1A 1252/4885MTNR1B 1645/4885 |
| US-20020119924-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | TNF, TNFRSF1A, TNFSF11 | AKR1C2 3000/4885MTNR1A 644/4885MTNR1B 444/4885 |
| US-20140356355-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | AKR1C2 2090/4885MTNR1A 1139/4885MTNR1B 2016/4885 |
| US-20120251547-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | AKR1C2 2090/4885MTNR1A 1139/4885MTNR1B 2016/4885 |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, IRAK1 | AKR1C2 2132/4885MTNR1A 177/4885MTNR1B 322/4885 |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | LTC4S, LTA4H, CYSLTR1 | AKR1C2 362/4885MTNR1A 1160/4885MTNR1B 1065/4885 |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PDE4A, PDE12, PDE3B | AKR1C2 1369/4885MTNR1A 223/4885MTNR1B 236/4885 |
| US-20200362045-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | AKR1C2 2090/4885MTNR1A 1139/4885MTNR1B 2016/4885 |
| US-20190151404-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEEASE | ELANE, SELE, FUT8 | AKR1C2 3363/4885MTNR1A 953/4885MTNR1B 995/4885 |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, PKD1, PKD2 | AKR1C2 143/4885MTNR1A 1811/4885MTNR1B 1806/4885 |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | AKR1C2 652/4885MTNR1A 358/4885MTNR1B 427/4885 |
| US-20040047863-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | TNF, TNFRSF1A, TNFSF11 | AKR1C2 3137/4885MTNR1A 617/4885MTNR1B 423/4885 |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | LTC4S, LTA4H, LTB4R2 | AKR1C2 209/4885MTNR1A 345/4885MTNR1B 262/4885 |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | IL1A, IL1B, IL1R1 | AKR1C2 1260/4885MTNR1A 1002/4885MTNR1B 1450/4885 |
| US-20160251443-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | AKR1C2 2090/4885MTNR1A 1139/4885MTNR1B 2016/4885 |
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, LTB4R2 | AKR1C2 383/4885MTNR1A 355/4885MTNR1B 360/4885 |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | IL17A, IL23R, IL15RA | AKR1C2 2090/4885MTNR1A 1139/4885MTNR1B 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.